https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)2021-08-09 09:43:272021-08-09 09:43:27Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 11542)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 11542)2021-08-09 09:41:192021-08-09 09:41:19Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-04 / Int J Mol Sci 2021 Aug;22(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-04 / Int J Mol Sci 2021 Aug;22(16)2021-08-04 00:00:002021-08-04 00:00:00Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-01 / Anticancer Res 2021 Aug;41(8):4133-4141
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-01 / Anticancer Res 2021 Aug;41(8):4133-41412021-08-01 00:00:002021-08-01 00:00:00Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-01 / Melanoma Res 2021 Aug;31(4):378-388
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-01 / Melanoma Res 2021 Aug;31(4):378-3882021-08-01 00:00:002023-01-31 12:55:32Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-30 / J Clin Transl Res 2021 Aug;7(4):485-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-30 / J Clin Transl Res 2021 Aug;7(4):485-5002021-07-30 00:00:002021-07-30 00:00:00Immune escape mechanisms and immunotherapy of urothelial bladder cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-25 / Res Vet Sci 2021 Jul;139:159-165
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-25 / Res Vet Sci 2021 Jul;139:159-1652021-07-25 00:00:002021-07-25 00:00:00Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-660
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-20 / Gynecol Oncol 2021 Sep;162(3):652-6602021-07-20 00:00:002023-03-14 09:44:20Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-19 / Sci Rep 2021 Jul;11(1):14661
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-19 / Sci Rep 2021 Jul;11(1):146612021-07-19 00:00:002021-07-19 00:00:00Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-04 / Cancer Immunol Immunother 2021 Jul;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
